Latest News

  • INSIGHTS

    16 Mar 2026

    Inside the High-Tech Rebirth of ADCs

  • PARTNERSHIPS

    10 Mar 2026

    New Roche Deal Targets B7H3 Tumors Worldwide

  • INNOVATION

    20 Feb 2026

    Taiho’s Calculated Gamble on Precision ADCs

  • REGULATORY

    12 Feb 2026

    A Faster Track for Myeloma Treatments?

Can Better ADC Engineering Unlock Solid Tumors?

Solve Therapeutics branding displayed on a Nasdaq digital billboard

INVESTMENT

9 Feb 2026

Solve Therapeutics raises $120M with backing from MSD and others, betting that smarter ADC design can finally unlock solid tumors

Antibody drug conjugate molecules supporting next-generation cancer therapy development

PARTNERSHIPS

23 Oct 2025

Faster or Failed? ADC Developers Rethink How Drugs Get Built

Invenra and Xcellon Biologics link discovery and manufacturing early to speed next-generation ADCs toward the clinic

FDA building representing regulatory review of antibody drug conjugates

INNOVATION

2 Oct 2025

Cancer’s guided missiles grow up

AbbVie, Pfizer and Merck advance antibody drug conjugates through late-stage trials and regulatory filings in a shift towards precision on...

Daiichi Sankyo research facility supporting antibody drug conjugate innovation

INNOVATION

16 Sep 2025

A Regulatory Signal That Precision Cancer Care Is Maturing

FDA backing for a next-generation ADC underscores growing confidence in targeted cancer drugs and signals faster momentum across oncology ...

Molecular structure of antibody drug conjugates advancing targeted cancer care

MARKET TRENDS

10 Feb 2025

Why ADCs Are Becoming Oncology’s Most Reliable Trend

Landmark ADC deals from 2023–2024 and new 2025 approvals underscore sustained momentum in targeted cancer care

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.